Since PSMA is a promising target for prostate cancer therapy and imaging, further elucidation of the relationship between TMPRSS2 gene fusions and PSMA could reveal novel pathways for enhancing targeted prostate cancer treatment. The gene discussed is FOLH1; the disease is prostate cancer.